دورية أكاديمية

Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials

التفاصيل البيبلوغرافية
العنوان: Effectiveness and safety of seven oral Chinese patent medicines as adjuvant therapy for cancer-related anemia: A systematic review and network meta-analysis of randomized controlled trials
المؤلفون: Jing Xu, Kang Wu, Xiao Li, Chiah Shean Teo, Guangda Li, Yiming Pan, Li Hou
المصدر: Journal of Traditional Chinese Medical Sciences, Vol 10, Iss 2, Pp 150-160 (2023)
بيانات النشر: Elsevier, 2023.
سنة النشر: 2023
المجموعة: LCC:Miscellaneous systems and treatments
مصطلحات موضوعية: Cancer-related anemia, Chinese patent medicine, Network meta-analysis, Effectiveness, Safety, Miscellaneous systems and treatments, RZ409.7-999
الوصف: Objective: To evaluate the effectiveness and safety of seven oral Chinese patent medicines (CPMs) as adjuvant therapy for cancer-related anemia (CRA) by network meta-analysis (NMA). Methods: A literature search to obtain randomized controlled trials (RCTs) of seven oral CPMs in the adjuvant treatment of CRA was conducted in multiple databases from the inception to April 2022. The RevMan5.3 and R 4.1.1 software were used for NMA. Results: We ultimately included 29 RCTs with 2140 patients. Traditional meta-analysis showed that Fufang E'jiao syrup (FFEJS), Shengxuebao mixture (SXBM), Shengxuening tablets (SXNT), Jianpi Shengxue granules (JPSXG), and Yixuesheng capsule (YXSC) combined with basic Western treatment (BWT) could improve the hemoglobin (HGB) level. JPSXG combined with BWT could improve the red blood cell (RBC). FFEJS combined with BWT improved the Karnofsky performance status (KPS). NMA showed that FFEJS, JPSXG, SXBM, and SXNT plus BWT improved HGB better than Shengxue tablets (SXT) plus BWT, with top three ranking results being JPSXG plus BWT > SXNT plus BWT > FFEJS plus BWT. FFEJS plus BWT, JPSXG plus BWT, SXBM plus BWT, SXNT plus BWT, and SXT plus BWT improved RBC better than BWT, with top three ranking results being SXNT plus BWT > JPSXG plus BWT > FFEJS plus BWT. In terms of the KPS score, compared with SXT plus BWT, FFEJS, JPSXG, SXBM, SXNT, and Yizhong Shengxue capsule (YZSXC) plus BWT had higher KPS, with top three ranking results being SXBM plus BWT > JPSXG plus BWT > FFEJS plus BWT. Conclusions: Our NMA demonstrated that seven oral CPMs used as adjuvant treatment of CRA had a definite clinical effect. JPSXG not only increases the levels of HGB and RBC to enhance the clinical effect but also improves patients' quality of life. More accurate conclusions need to be verified by more high-quality RCTs.
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 2095-7548
Relation: http://www.sciencedirect.com/science/article/pii/S2095754823000108; https://doaj.org/toc/2095-7548
DOI: 10.1016/j.jtcms.2023.03.004
URL الوصول: https://doaj.org/article/fa43c983415c49a987ad0abe12c3e1a9
رقم الأكسشن: edsdoj.fa43c983415c49a987ad0abe12c3e1a9
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:20957548
DOI:10.1016/j.jtcms.2023.03.004